{"nctId":"NCT01348269","briefTitle":"Assessment of Efficacy of Zoledronic Acid in the Treatment of Bone Marrow Edema Syndrome","startDateStruct":{"date":"2011-05","type":"ACTUAL"},"conditions":["Bone Marrow Edema"],"count":48,"armGroups":[{"label":"Aclasta","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aclasta"]},{"label":"NaCl Solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclasta","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men: age over ≥ 18 years or women: age over ≥ 18 years with finished reproductivity according to the following definition:\n* ≥ 12 month persistent natural (spontaneous) amenorrhoea (women aged \\<50: additionally: FSH \\>40MIE/ml and estrogen deficiency of \\<30pg/ml or a negative estrogen test)\n* status post hysterectomy and / or bilateral oophorectomy\n* finished reproduction planning\n* secure diagnosis of bone marrow edema using MRT\n* current osteologic basic laboratory values (≤ 4 weeks before V2) according to DVO criteria\n* presence of an personally signed informed consent for the participation in the study\n\nExclusion Criteria:\n\n* \\- subchondral bone loss or already occurred cartilage damage due to the bone marrow edema\n* reactive bone marrow edema with advanced arthrotic changes in the adjacent joint (grade III and IV according to Kellgren and Lawrence)\n* patients with edematous changes in bone marrow due to the diagnosis of M. Sudeck / algodystrophy / Complex Regional Pain Syndrome (CRPS)\n* patients with known hypo- and hyperparathyroidism, osteogenesis imperfecta, osteomalacia, M. Paget or another systemic skeletal diseases, except osteoporosis\n* patients with bone necrosis in the painful skeletal region\n* patients with infectious process at the affected bone or the adjacent joint and adjacent soft parts, respectively\n* patients with diagnosed or assumed rheumatoid arthritis, Lupus erythematodes, collagenosis or vasculitides\n* patients with advanced renal insufficiency (GFR according to Cockcroft\n\n  / Gault ≤ 40 ml/min/KO)\n* patients with malignant diseases with osseous manifestation in anamnesis/history\n* status post malignant basic/primary disease with large dosed chemotherapy\n* current or massive dose therapy completed before less than 6 weeks (\\>7.5mg prednisolon equivalent) with glucocorticoids\n* patients with a malignant tumor disease within the past 5 years, independent from the affected organ system and independent from the implemented treatment, the presence of a relapse or metastatic invasion, except basal cell carcinoma and squamous-cell carcinoma of the skin Current treatment due to uveitis\n* vague/ambiguous hyper- or hypocalcemia, hyper- or hypophosphatemia\n* etiological vague/ambiguous AP-increase\n* symptomatic renal calculus or nephrocalcinosis within 2 years before V2\n* recent fracture within the last 3 months independent of the localisation\n* non consolidated fractures\n* previous treatment with i.v. bisphosphonates within the last 12 months\n* previous treatment with oral bisphosphonates within the last 12 months and longer than 3 months\n* pre-treatment with prostacyclin analogs (Ilomedin® / Iloprost®) within the past 6 months\n* Current treatment due to inflammatory diseases of the jaw area as well as planned tooth extractions or tooth extractions less than 6 months ago or oral surgery implant treatment\n* pregnancy or nursing period\n* patients immediately involved in the conduction of the trial and relatives\n* patients with current proceedings related to the bone marrow edema\n* patients for which the participation in the study carries an increased risk under consideration of the health condition due to the assessment of the investigator\n* participation in another clinical trial within 30 days before study start or during the trial\n* participation of patient who might be dependent on the investigator, also the spouse, parents or children","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction of the Edema Area","description":"The volume of the edema in cm³ is defined as biometric data measured by the use of MRI before and six weeks after treatment. Edema volume at screening was set to 100%. Edema volume six weeks after study drug administration was provdied as percentage reduction compared to the value at screening","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.53","spread":"41.92"},{"groupId":"OG001","value":"23.97","spread":"46.52"}]}]}]},{"type":"SECONDARY","title":"Reduction of Pain (VAS)","description":"Reduction of pain as measured by a Visual Analog Scale (VAS). Range 0-100 with higher values indicating worse pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":"22.7"},{"groupId":"OG001","value":"25.6","spread":"24.4"}]}]}]},{"type":"SECONDARY","title":"Reduction of Pain","description":"Reduction of pain as measured by a visual analog scale (VAS). Range 0-100. Higher values indicating worse pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"28.7"},{"groupId":"OG001","value":"38.5","spread":"30.2"}]}]}]},{"type":"SECONDARY","title":"Quality of Life (Qualeffo-41 Questionnaire)","description":"Quality of life as measured by the Qualeffo-41 questionnaire - a quality of life questionnaire in patients with fractures of the European Foundation for Osteoporosis Higher values indicate worse quality of life","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"0.4"},{"groupId":"OG001","value":"2.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Quality of Life (Qualeffo-41 Questionnaire)","description":"Quality of life as measured by the Qualeffo-41 questionnaire - a quality of life questionnaire in patients with vertebral fractures of the European Foundation for Osteoporosis","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"0.5"},{"groupId":"OG001","value":"2.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Subjective Estimation of Medical Condition (PDI)","description":"Subjective estimation of medical condition as assessed by PDI (Pain Disability Index). Range 0-70. The higher the index the greater the person's disability due to pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"5.8"},{"groupId":"OG001","value":"20.5","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Subjective Estimation of Medical Condition (PDI)","description":"Subjective estimation of medical condition as assessed by PDI (Pain Disability Index)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"6.0"},{"groupId":"OG001","value":"18.8","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Number of Additional Medicinal Visits","description":"Number of additional medicinal visits until week 3","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Additional Medicinal Visits","description":"Aggregated number of unscheduled medicinal visits","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Illness","description":"Aggregated number of days of illness i.e. sick leave from work, assessed until week 6","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.24","spread":"5.02"},{"groupId":"OG001","value":"3.00","spread":"7.63"}]}]}]},{"type":"SECONDARY","title":"Number of Days of Illness","description":"Number of days of illness assessed until week 6","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"4.10"},{"groupId":"OG001","value":"3.14","spread":"4.10"}]}]}]},{"type":"SECONDARY","title":"Number of Aseptic Bone Necrosis and Fatigue Fractures","description":"Assessment of number of patients withaseptic bone necrosis and/or fatigue fractures.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","description":"including changes in the following parameters according to DVO guidelines: Calcium, Phosphate, Creatinin-Clearance (Cockcroft-Gault), Alkaline Phosphatase, γGT, CRP","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":34},"commonTop":["Headache","Pain in extremity","Fatigue","Chills","Pyrexia"]}}}